Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism

Breast Cancer Research

Volumn 15, Issue 3, 2013, Pages

  Nguyen Vu, Trang ^a   Vedin, Lise Lotte ^b   Liu, Ka ^a   Jonsson, Philip ^a   Lin, Jean Z ^a,c   Candelaria, Nicholes R ^a   Candelaria, Lindsay P ^a   Addanki, Sridevi ^a   Williams, Cecilia ^a   Gustafsson, Jan Åke ^a,b,c   Steffensen, Knut R ^b   Lin, Chin Yo ^a  

^a University of Houston   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

breast cancer; E2F; ligand; Liver receptor; microarray; nuclear receptor

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ANTINEOPLASTIC AGENT; BETA ACTIN; LIVER X RECEPTOR; LIVER X RECEPTOR LIGAND; MESSENGER RNA; TRANSCRIPTION FACTOR E2F2; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; BENZYLAMINE DERIVATIVE; E2F2 PROTEIN, HUMAN; LIGAND; ORPHAN NUCLEAR RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING SITE; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; GENETIC ASSOCIATION; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION INITIATION SITE; UPREGULATION; BIOSYNTHESIS; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BENZOATES; BENZYLAMINES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; E2F2 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; ORPHAN NUCLEAR RECEPTORS; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC;

EID: 84879447129     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3443     Document Type: Article

References (37)

1. Obiorah I, Jordan VC. Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas 2011, 70:315-321. 10.1016/j.maturitas.2011.09.006, 3518840, 21982237.
2. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, Ajani JA. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 2011, 29:3328-3330. 10.1200/JCO.2011.36.0354, 21788567.
3. Engel RH, Kaklamani VG. HER2-positive breast cancer: current and future treatment strategies. Drugs 2007, 67:1329-1341. 10.2165/00003495-200767090-00006, 17547474.
4. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010, 363:1938-1948. 10.1056/NEJMra1001389, 21067385.
5. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004, 3:950-964. 10.1038/nrd1551, 15520817.
6. Steffensen KR, Gustafsson JA. Putative metabolic effects of the liver × receptor (LXR). Diabetes 2004, 53(Suppl 1):S36-42.
7. Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med 2006, 57:313-329. 10.1146/annurev.med.57.121304.131428, 16409152.
8. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J, Tippin TK, Wang X, Lusis AJ, Hsueh WA, Law RE, Collins JL, Willson TM, Tontonoz P. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002, 99:7604-7609. 10.1073/pnas.112059299, 124297, 12032330.
9. Tontonoz P, Mangelsdorf DJ. Liver × receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003, 17:985-993. 10.1210/me.2003-0061, 12690094.
10. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000, 97:12097-12102. 10.1073/pnas.200367697, 17300, 11035776.
11. Zelcer N, Tontonoz P. Liver × receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006, 116:607-614. 10.1172/JCI27883, 1386115, 16511593.
12. Yang C, McDonald JG, Patel A, Zhang Y, Umetani M, Xu F, Westover EJ, Covey DF, Mangelsdorf DJ, Cohen JC, Hobbs HH. Sterol intermediates from cholesterol biosynthetic pathway as liver × receptor ligands. J Biol Chem 2006, 281:27816-27826. 10.1074/jbc.M603781200, 16857673.
13. Jakobsson T, Treuter E, Gustafsson JA, Steffensen KR. Liver × receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci 2012, 33:394-404. 10.1016/j.tips.2012.03.013, 22541735.
14. Chuu CP. Modulation of liver × receptor signaling as a prevention and therapy for colon cancer. Med Hypotheses 2011, 76:697-699. 10.1016/j.mehy.2011.01.037, 21333456.
15. Chuu CP, Kokontis JM, Hiipakka RA, Liao S. Modulation of liver × receptor signaling as novel therapy for prostate cancer. J Biomed Sci 2007, 14:543-553. 10.1007/s11373-007-9160-8, 17372849.
16. Chuu CP, Lin HP. Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer Res 2010, 30:3643-3648.
17. Fukuchi J, Kokontis JM, Hiipakka RA, Chuu CP, Liao S. Antiproliferative effect of liver × receptor agonists on LNCaP human prostate cancer cells. Cancer Res 2004, 64:7686-7689. 10.1158/0008-5472.CAN-04-2332, 15520170.
18. Gabbi C, Kim HJ, Barros R, Korach-Andre M, Warner M, Gustafsson JA. Estrogen-dependent gallbladder carcinogenesis in LXRbeta-/- female mice. Proc Natl Acad Sci USA 2010, 107:14763-14768. 10.1073/pnas.1009483107, 2930435, 20679224.
19. Vedin LL, Gustafsson JA, Steffensen KR. The oxysterol receptors LXRalpha and LXRbeta suppress proliferation in the colon. Mol Carcinog 2012, doi: 10.1002/mc.21924.
20. Vedin LL, Lewandowski SA, Parini P, Gustafsson JA, Steffensen KR. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis 2009, 30:575-579. 10.1093/carcin/bgp029, 19168586.
21. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B Met 1995, 57:289-300.
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
23. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, Yeo A, George J, Kuznetsov VA, Lee YK, Charn TH, Palanisamy N, Miller LD, Cheung E, Katzenellenbogen BS, Ruan Y, Bourque G, Wei CL, Liu ET. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 2007, 3:e87. 10.1371/journal.pgen.0030087, 1885282, 17542648.
24. Merrell KW, Crofts JD, Smith RL, Sin JH, Kmetzsch KE, Merrell A, Miguel RO, Candelaria NR, Lin CY. Differential recruitment of nuclear receptor coregulators in ligand-dependent transcriptional repression by estrogen receptor-alpha. Oncogene 2011, 30:1608-1614. 10.1038/onc.2010.528, 21102521.
25. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
26. Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006, 66:7334-7340. 10.1158/0008-5472.CAN-05-4269, 16849584.
27. Finlin BS, Gau CL, Murphy GA, Shao H, Kimel T, Seitz RS, Chiu YF, Botstein D, Brown PO, Der CJ, Tamanoi F, Andres DA, Perou CM. RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. J Biol Chem 2001, 276:42259-42267. 10.1074/jbc.M105888200, 11533059.
28. Soulez M, Parker MG. Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling. J Mol Endocrinol 2001, 27:259-274. 10.1677/jme.0.0270259, 11719280.
29. Lin CY, Strom A, Vega VB, Kong SL, Yeo AL, Thomsen JS, Chan WC, Doray B, Bangarusamy DK, Ramasamy A, Vergara LA, Tang S, Chong A, Bajic VB, Miller LD, Gustafsson JA, Liu ET. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol 2004, 5:R66. 10.1186/gb-2004-5-9-r66, 522873, 15345050.
30. Venkateswaran A, Repa JJ, Lobaccaro JM, Bronson A, Mangelsdorf DJ, Edwards PA. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem 2000, 275:14700-14707. 10.1074/jbc.275.19.14700, 10799558.
31. Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, Kaminski WE, Schmitz G. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun 1999, 257:29-33. 10.1006/bbrc.1999.0406, 10092505.
32. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998, 12:2245-2262. 10.1101/gad.12.15.2245, 9694791.
33. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002, 3:11-20.
34. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000, 14:2819-2830. 10.1101/gad.844900, 317055, 11090130.
35. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. Role of LXRs in control of lipogenesis. Genes Dev 2000, 14:2831-2838. 10.1101/gad.850400, 317060, 11090131.
36. Viry E, Anwar A, Kirsch G, Jacob C, Diederich M, Bagrel D. Antiproliferative effect of natural tetrasulfides in human breast cancer cells is mediated through the inhibition of the cell division cycle 25 phosphatases. Int J Oncol 2011, 38:1103-1111.
37. Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G, Ranashinge M, Cady B, Pagano M, Loda M. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest 2000, 106:753-761. 10.1172/JCI9174, 381390, 10995786.